Emflaza (Deflazacort)

A Treatment for Duchenne Muscular Dystrophy (DMD)

EMFLAZA®is the brand name for deflazacort, a corticosteroid that was approved by the Federal Drug Administration (FDA) on February 9th, 2017. It is used for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.

Frequently Asked Questions About EMFLAZA®

Is my son eligible for EMFLAZA®?

EMFLAZA® potentially may treat all forms of DMD, regardless of genetic mutation. Individual circumstances and experiences may vary, however. It’s important to talk with your physician about whether treatment with EMFLAZA®is right for your child.

How does EMFLAZA® work?

EMFLAZA® demonstrates anti-inflammatory and immunosuppressant effects.

How is EMFLAZA® given to patients?

EMFLAZA®is available both as a tablet and as an oral suspension. Both can be taken with or without food. EMFLAZA®tablets can be taken whole or crushed and taken immediately after mixing with applesauce. EMFLAZA®oral suspension should be shaken well before taking and used only with the dispenser provided with the prescription.

What is the benefit of EMFLAZA®?

In clinical studies, those treated with EMFLAZA®showed improved muscle strength and a slower decline in functional ability. It has also been shown to preserve cardiac and respiratory function and reduce the incidence of scoliosis in boys with DMD.

Is EMFLAZA® different from other corticosteroids?

In clinical trials, patients treated with EMFLAZA®  experienced to those who were treated with prednisone, However, those who received EMFLAZA®experienced fewer severe side effects such as weight gain, glucose intolerance (diabetes), loss of bone mass and behavioral issues.

Is EMFLAZA® covered by insurance?

Insurance coverage varies from plan to plan and it will require prior authorization. Depending on your insurance review process, prior authorization rate of acquisition may vary.